The April 29 approval of Seattle-based Dendreon's prostate cancer vaccine, Provenge (sipuleucel ... controlled trial (Immunotherapy for Prostate Adenocarcinoma Treatment; IMPACT), the results ...
The two trials randomized patients 2:1 to receive either sipuleucel-T immunotherapy—autologous peripheral blood mononuclear cells loaded with a recombinant fusion protein comprising prostatic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback